MedTrace Logo

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT04930562 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-17

Study results available
· View outcomes & findings →

Summary

This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.

Conditions

  • GVHD, Chronic

Interventions

DRUG

BN101

BN101 is an orally ROCK2 selective inhibitor

Sponsors & Collaborators

  • BioNova Pharmaceuticals (Shanghai) LTD.

    lead INDUSTRY

Principal Investigators

  • Depei Wu, Prof · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-27
Primary Completion
2022-06-10
Completion
2022-12-10
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930562 on ClinicalTrials.gov